NK cell modulation by JAK inhibition

scientific article published on 31 August 2015

NK cell modulation by JAK inhibition is …
instance of (P31):
editorialQ871232
scholarly articleQ13442814

External links are
P356DOI10.18632/ONCOSCIENCE.224
P932PMC publication ID4580057
P698PubMed publication ID26425655
P5875ResearchGate publication ID282362299

P2093author name stringDominik Wolf
Janna Rudolph
Kathrin Schönberg
P2860cites workFunctions of natural killer cellsQ29614300
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisQ33399980
JAK Inhibition Impairs NK Cell Function in Myeloproliferative NeoplasmsQ41127061
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.Q53175859
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?Q54393708
Activity of therapeutic JAK 1/2 blockade in graft-versus-host diseaseQ87635679
P433issue8
P304page(s)677-678
P577publication date2015-08-31
P1433published inOncoscienceQ27725796
P1476titleNK cell modulation by JAK inhibition
P478volume2

Reverse relations

cites work (P2860)
Q49904873Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats - Comparison of juvenile and adult responses.
Q39145689STAT3 activation in infection and infection-associated cancer

Search more.